Drug intelligence / Profile preview

Monoclonal antibody CAL

Development stage: Discontinued
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

Monoclonal antibody CAL is a humanized monoclonal antibody directed against parathyroid hormone-related protein (PTH-rP). It is designed to target and bind specifically to PTH-rP, which plays a role in certain cancers, particularly those associated with hypercalcemia. By binding to this protein, the drug may help inhibit its activity and potentially reduce tumor growth or related symptoms[1].

Other names: humanized anti-PTHrP monoclonal antibodyanti-PTHrP antibodyhumanized monoclonal antibody to PTHrP

Beyond the preview

Go deeper on Monoclonal antibody CAL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Monoclonal antibody CAL.

Explore the full profile